IN2014DN03464A - - Google Patents

Download PDF

Info

Publication number
IN2014DN03464A
IN2014DN03464A IN3464DEN2014A IN2014DN03464A IN 2014DN03464 A IN2014DN03464 A IN 2014DN03464A IN 3464DEN2014 A IN3464DEN2014 A IN 3464DEN2014A IN 2014DN03464 A IN2014DN03464 A IN 2014DN03464A
Authority
IN
India
Prior art keywords
providing neuroprotection
stroke
mirna
administering
variant
Prior art date
Application number
Other languages
English (en)
Inventor
Suh hang H JUO
Yung Song Wang
Hsin Yun Cheng
Original Assignee
Dcb Usa Llc
Univ Kaohsiung Medical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dcb Usa Llc, Univ Kaohsiung Medical filed Critical Dcb Usa Llc
Publication of IN2014DN03464A publication Critical patent/IN2014DN03464A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
IN3464DEN2014 2011-11-03 2012-11-05 IN2014DN03464A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161555152P 2011-11-03 2011-11-03
PCT/US2012/063604 WO2013067531A2 (en) 2011-11-03 2012-11-05 Methods of using microrna 195 in providing neuroprotection

Publications (1)

Publication Number Publication Date
IN2014DN03464A true IN2014DN03464A (zh) 2015-06-05

Family

ID=48193054

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3464DEN2014 IN2014DN03464A (zh) 2011-11-03 2012-11-05

Country Status (7)

Country Link
US (1) US9315812B2 (zh)
EP (1) EP2773381B1 (zh)
JP (1) JP5888572B2 (zh)
CN (1) CN104080910A (zh)
IN (1) IN2014DN03464A (zh)
TW (1) TWI462741B (zh)
WO (1) WO2013067531A2 (zh)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2916989A1 (en) * 2013-06-28 2014-12-31 London Health Sciences Centre Research Inc. Inhibition of microrna for treatment of sepsis
CN106474549B (zh) * 2016-11-21 2019-05-03 南通大学 MicroRNA基因介导的新型组织工程化神经的构建及其在修复神经缺损的应用
US11040055B2 (en) 2016-12-14 2021-06-22 China Medical University Method of treating diabetic retinopathy or wet type adult macular degeneration
JP2023512688A (ja) * 2020-02-03 2023-03-28 ラトガース，ザ ステート ユニバーシティ オブ ニュー ジャージー 脊髄損傷後の機能回復を促進するためのマイクロｒｎａ－７組成物およびその使用方法
TW202206093A (zh) * 2020-08-12 2022-02-16 中國醫藥大學 Ｓｅｍａ３ｄ拮抗劑用於預防或治療神經退化性疾病以及延長壽命之用途
CN113599540B (zh) * 2021-05-27 2023-05-23 山西医科大学 miRNA-195-5p在制备抑制或降低麦芽酚铝所致神经细胞损伤的试剂中的应用
CN113308535A (zh) * 2021-06-11 2021-08-27 中国人民解放军空军军医大学 一种基于血清外泌体miRNA的PD诊断及分期试剂盒

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
CA2533701A1 (en) * 2003-07-31 2005-02-17 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for use in modulation of small non-coding rnas
CA2554818A1 (en) * 2004-02-09 2005-08-25 Thomas Jefferson University Diagnosis and treatment of cancers with microrna located in or near cancer-associated chromosomal features
WO2008088858A2 (en) * 2007-01-17 2008-07-24 The Johns Hopkins University Compositions and methods featuring micronas for treating neoplasia
JP5654352B2 (ja) * 2007-11-09 2015-01-14 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム ｍｉＲ−１５ファミリーのマイクロＲＮＡによる心筋細胞生存及び心臓修復の調節
US20110117111A1 (en) * 2008-03-26 2011-05-19 Johns Hopkins University Microrna-based diagnostic testing and therapies for inflammatory bowel disease and related diseases
EP2112235A1 (en) 2008-04-24 2009-10-28 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Compositions and methods for microRNA expression profiling of nasopharyngeal carcinoma
EP2239675A1 (en) * 2009-04-07 2010-10-13 BIOCRATES Life Sciences AG Method for in vitro diagnosing a complex disease
WO2010151640A2 (en) 2009-06-24 2010-12-29 Board Of Regents Of The University Of Nebraska Compositions and methods for the diagnosis and treatment of inflammatory disorders and fibrotic disease
US8354520B2 (en) * 2009-12-10 2013-01-15 Kaohsiung Medical University Composition and method for treating atherosclerosis, method for determining if a subject has atherosclerosis and method of screening an anti-atherosclerotic drug

Also Published As

Publication number Publication date
CN104080910A (zh) 2014-10-01
US20140294943A1 (en) 2014-10-02
EP2773381A2 (en) 2014-09-10
TWI462741B (zh) 2014-12-01
US9315812B2 (en) 2016-04-19
WO2013067531A3 (en) 2014-07-03
JP5888572B2 (ja) 2016-03-22
JP2014533248A (ja) 2014-12-11
EP2773381B1 (en) 2020-06-03
EP2773381A4 (en) 2015-07-08
TW201322987A (zh) 2013-06-16
WO2013067531A2 (en) 2013-05-10

Similar Documents

Publication Publication Date Title
MX2019011905A (es) Nuevas composiciones para el tratamiento de la esclerosis lateral amiotrofica.
EP2757887A4 (en) PYRROLOPYRIDINONE COMPOUNDS AND METHOD FOR THE TREATMENT OF HIV
EP2736528A4 (en) COMPOSITIONS AND METHODS OF TREATING HIV
EP2938616A4 (en) PROCESS FOR THE PREPARATION OF TOFACITINIB AND INTERMEDIATES
IN2014DN03464A (zh)
MX368649B (es) Mezclas fungicidas de penflufén.
MX364495B (es) Composición para usarse en el tratamiento de enfermedades oculares relacionadas con ácidos nucleicos.
IN2012MU03723A (zh)
PL2763527T3 (pl) Sposób obróbki grzybobójczej odpornych szczepów przy użyciu jednego lub więcej olejków eterycznych
ZA201306990B (en) Methods and compositions for treating, reducing, or preventing damage to the nervous system of animals
MX2014010433A (es) Nueva forma cristalina de sulfato de sitagliptina.
ZA201404327B (en) Composition comprising block cocondensates of propylfunctional alkaline siliconates and silicates, and method for the production thereof
PL2997173T3 (pl) Sposób wytwarzania stali powleczonej cynkiem do utwardzania w procesie tłoczenia na gorąco
EP2758780A4 (en) METHOD OF TREATING MULTIPLE SCLEROSIS
EP2739332A4 (en) STOPPERS / PISTONS FOR CARCASES OF A SPRAYING CARPULAR ARRANGEMENT
IL229706A0 (en) A method for treating the effects of a stroke
MX2015003034A (es) Jeringa que contiene una composicion, en particular farmaceutica, que comprende inmunoglobulinas, su metodo de fabricacion y uso.
EP2683404A4 (en) METHOD FOR TREATING AMYOTROPHER LATERAL SCLEROSIS
HRP20180417T1 (hr) Pripravak za liječenje poremećaja hipoaktivne seksualne želje
HUE038149T2 (hu) Eljárás acél kezelésére
HK1209052A1 (zh) 治療賽多孢子菌屬感染的方法
HRP20150141T1 (en) Use of nifuratel to treat infections caused by clostridium species
IN2013CH05865A (zh)
UA65592U (ru) Способ лечения ассоциативных бактериозов животных
UA106373C2 (ru) Применение поллентара как средства фригопротекторного действия